TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10661332

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (ifosfamide, etoposide, high-dose methotrexate, cisplatin, cytarabine)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Immediate postoperative radiotherapy with vincristine followed by maintenance chemotherapy (cisplatin, CCNU, vincristine)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (arm I)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Immediate postoperative radiotherapy (arm II)
Number of subjects: 158
Study: 9051202

Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vitamin C (250 mg)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Beta-carotene (15 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 8339829

Group type: EXPERIMENTAL
Intervention: Subzonal insemination (SUZI)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Normal insemination
Number of subjects: 48
Study: 2871951

Group type: EXPERIMENTAL
Intervention: Fenoldopam
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 29264729

Group type: EXPERIMENTAL
Intervention: PVI + RSD
Number of subjects: 69

Group type: COMPARATOR
Intervention: PVI + spironolactone
Number of subjects: 69
Study: 26892409

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2771

Group type: COMPARATOR
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 2771
Study: 24326604

Group type: EXPERIMENTAL
Intervention: Rapid PCR
Number of subjects: 300

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 300
Study: 22781725

Group type: EXPERIMENTAL
Intervention: IM + IFN
Number of subjects: 155
Study: 20350693

Group type: EXPERIMENTAL
Intervention: Ultrafiltration (UF)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Continuous intravenous diuretics (IV)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Bolus diuretics
Number of subjects: 200
Study: 17967134

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg/d
Number of subjects: 38

Group type: COMPARATOR
Intervention: Calcium 1 g/d and vitamin D 800 UI/d
Number of subjects: 38
Study: 15984982

Group type: EXPERIMENTAL
Intervention: 2 mg neostigmine
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 2 mg neostigmine + 0.4 mg glycopyrrolate
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 13
Study: 12712026

Group type: EXPERIMENTAL
Intervention: Normal saline solution
Number of subjects: 530

Group type: COMPARATOR
Intervention: Running tap water
Number of subjects: 530
Study: 10711322

Group type: EXPERIMENTAL
Intervention: Closed formulary
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open formulary
Number of subjects: 0
Study: 7474041

Group type: EXPERIMENTAL
Intervention: 6.9% carbohydrate-electrolyte solution (CHO)
Number of subjects: 9
Study: 1849786

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (cisplatin at 70 mg/m2 i.v. on day 1 and etoposide at 100 mg/m2 i.v. on day 1 and 200 mg/m2 orally on days 2 and 3)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 87
Study: 6891844

Group type: EXPERIMENTAL
Intervention: Chemotherapy with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination of different cytostatic drugs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modern chemotherapy with cisplatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 0
Study: 31134601

Group type: EXPERIMENTAL
Intervention: Clinical simulation teaching course
Number of subjects: 392

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 392
Study: 28054322

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g/d for 5 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine supplementation (responders only)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (responders only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Creatine supplementation and Placebo
Number of subjects: 30
Study: 25756173

Group type: EXPERIMENTAL
Intervention: High sucrose intake (≥ 10 E%)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Low sucrose intake (< 10 E%)
Number of subjects: 1062
Study: 23789911

Group type: EXPERIMENTAL
Intervention: 25 g glucose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 60 g glucose
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 21208479

Group type: EXPERIMENTAL
Intervention: Intervention group (n=102)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intervention group (n=144 for canteen analysis)
Number of subjects: 102
Study: 20122586

Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg loading infusion followed by 0.04 mg/kg/min infusion)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (saline group)
Number of subjects: 30
Study: 17717930

Group type: EXPERIMENTAL
Intervention: Xiaobai Decoction (XBD)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Conventional treatment with magnesium sulfate
Number of subjects: 85
Study: 14586719

Group type: EXPERIMENTAL
Intervention: Losartan (25 to 100 mg/day)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Amlodipine (2.5 to 5 mg/day)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 86

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 86
Study: 10776007

Group type: EXPERIMENTAL
Intervention: 100-mg slow-release aspirin (Disprin CV) daily
Number of subjects: 216

Group type: COMPARATOR
Intervention: Routine antenatal care
Number of subjects: 216
Study: 8924063

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg twice daily
Number of subjects: 207

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 207
Study: 1579511

Group type: EXPERIMENTAL
Intervention: High-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Number of subjects: 40

Group type: COMPARATOR
Intervention: Low-dose oral bacteriotherapy using a combination of anaerobe fecal Lactobacilli
Number of subjects: 40
Study: 3898417

Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine at night
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 31236796

Group type: EXPERIMENTAL
Intervention: Vibration hypoxic exposure group (HWBV; n=9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Vibration normoxic exposure group (NWBV; n=10)
Number of subjects: 19
Study: 29855447

Group type: EXPERIMENTAL
Intervention: Quadriceps muscle fatigue group (n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Calf muscles fatigue group (n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (n=15)
Number of subjects: 45
Study: 27030303

Group type: EXPERIMENTAL
Intervention: Individualized yoga intervention
Number of subjects: 101

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 101
Study: 24661055

Group type: EXPERIMENTAL
Intervention: Interventions that provided experience with counterstereotypical exemplars
Number of subjects: 17021

Group type: EXPERIMENTAL
Intervention: Interventions using evaluative conditioning methods
Number of subjects: 17021

Group type: EXPERIMENTAL
Intervention: Interventions providing strategies to override biases
Number of subjects: 17021

Group type: COMPARATOR
Intervention: Interventions engaging participants with others' perspectives
Number of subjects: 17021

Group type: COMPARATOR
Intervention: Interventions asking participants to consider egalitarian values
Number of subjects: 17021

Group type: COMPARATOR
Intervention: Interventions inducing a positive emotion
Number of subjects: 17021

Group type: EXPERIMENTAL
Intervention: Interventions invoking high self-involvement
Number of subjects: 17021

Group type: EXPERIMENTAL
Intervention: Interventions linking Black people with positivity and White people with negativity
Number of subjects: 17021

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 17021
Study: 22847373

Group type: EXPERIMENTAL
Intervention: Thiopental plus ketamine (0.5 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Thiopental alone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (Thiopental alone and Thiopental plus ketamine)
Number of subjects: 24
Study: 20535265

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 120
Study: 18018805

Group type: EXPERIMENTAL
Intervention: Primary medical care (cumulative number of visits: 0, 1, >= 2)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Primary medical care (>= 2 visits)
Number of subjects: 298
Study: 16148375

Group type: EXPERIMENTAL
Intervention: Standard therapy plus enalapril (10‐20 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Standard therapy plus Accupro (slow titration from 5 to a maximum 20 mg/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard therapy (glycosides, diuretics, peripheral vasodilators)
Number of subjects: 31
Study: 12115175

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 400 mg/day
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 800 mg/day
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) 1200 mg/day
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (HCQ) levels
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Bisdesethylchloroquine (BDCQ) levels
Number of subjects: 212
Study: 10471564

Group type: COMPARATOR
Intervention: Heparin (10 U/ml)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Heparin and Vancomycin (10 U/ml and 25 microg/ml)
Number of subjects: 117
Study: 8742262

Group type: EXPERIMENTAL
Intervention: Memory for spatial frequency measured in separate blocks of trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory for contrast measured in separate blocks of trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Memory for spatial frequency and contrast measured in an uncertainty paradigm
Number of subjects: 0
Study: 2291418

Group type: EXPERIMENTAL
Intervention: Oral zinc supplementation (45-90 mg of Zn2+, as zinc sulfate)
Number of subjects: 20
Study: 7317899

Group type: COMPARATOR
Intervention: Nifedipine 0 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Nifedipine 90 mg
Number of subjects: 10
Study: 31504721

Group type: EXPERIMENTAL
Intervention: High-sodium, high-cheese intervention (HNaC; 5500 mg/d sodium, 170 g/d cheese)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Low-sodium, high-cheese intervention (LNaC; 1500 mg/d sodium, 170 g/d cheese)
Number of subjects: 11

Group type: COMPARATOR
Intervention: High-sodium, no-dairy intervention (HNa; 5500 mg/d sodium)
Number of subjects: 11
Study: 30845791

Group type: EXPERIMENTAL
Intervention: Solar salt aged for 3 years (SS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purified salt (PS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bamboo salt recrystalized 3 times (BS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-starter (SSMJ)
Number of subjects: 0
Study: 28716147

Group type: EXPERIMENTAL
Intervention: 6-week Gold Standard Programme (GSP)
Number of subjects: 110

Group type: COMPARATOR
Intervention: treatment as usual (control)
Number of subjects: 110
Study: 25683074

Group type: EXPERIMENTAL
Intervention: Selective transperitoneal needle aspiration of a bowel loop (STAB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional maneuvers (Control)
Number of subjects: 44
Study: 25200141

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Canagliflozin 200 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (normal renal function or mild renal impairment)
Number of subjects: 24
Study: 22270485

Group type: EXPERIMENTAL
Intervention: PRECOOL
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: HEAT
Number of subjects: 13

Group type: COMPARATOR
Intervention: CONTROL
Number of subjects: 13
Study: 19571529

Group type: EXPERIMENTAL
Intervention: Diastolic WSS
Number of subjects: 379

Group type: EXPERIMENTAL
Intervention: Systolic WSS
Number of subjects: 379
Study: 17634109

Group type: EXPERIMENTAL
Intervention: Active counselling (educational intervention about the continuous dopaminergic hypothesis)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Standard management (control group)
Number of subjects: 83
Study: 15220170

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 83

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 83
Study: 11274545

Group type: EXPERIMENTAL
Intervention: MS-325 at 0.01 mmol/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MS-325 at 0.03 mmol/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MS-325 at 0.05 mmol/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MS-325 at 0.01 and 0.03 mmol/kg
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: MS-325 (all doses)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Conventional contrast agent-enhanced angiography
Number of subjects: 26
Study: 9557374

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg bid)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7983579

Group type: EXPERIMENTAL
Intervention: Black source
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low involvement message processing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attitudes toward the source's ethnic group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Distraction paradigm
Number of subjects: 0

Group type: COMPARATOR
Intervention: White participants
Number of subjects: 0
Study: 2463702

Group type: EXPERIMENTAL
Intervention: Stable epidural opioid treatment (median dose: 90 mg morphine/24 hours, range 16‐600)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Stable epidural opioid treatment
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Epidural opioid treatment of neurogenic pain
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Epidural opioid treatment in low dosage group (less than 300 mg morphine/24 hours)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Epidural opioid treatment in high dosage group (equal or greater than 300 mg morphine/24 hours)
Number of subjects: 48
Study: 229506

Group type: EXPERIMENTAL
Intervention: ACTH-fragment 4-10 (30 mg SC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31099281

Group type: EXPERIMENTAL
Intervention: Xiaoaiping (combined with routine chemotherapy)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Routine chemotherapy only (control group)
Number of subjects: 93
Study: 28215654

Group type: EXPERIMENTAL
Intervention: Docetaxel + DCvac
Number of subjects: 43

Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 43
Study: 25119055

Group type: EXPERIMENTAL
Intervention: Pinless navigation
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 100
Study: 24084548

Group type: COMPARATOR
Intervention: Staples
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Subcuticular suture
Number of subjects: 63
Study: 19825898

Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol pretreatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 25
Study: 19264686

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 16179207

Group type: EXPERIMENTAL
Intervention: Semiautomated measurements of mesothelioma tumor thickness
Number of subjects: 22
Study: 12781509

Group type: EXPERIMENTAL
Intervention: Surgery to treat end-stage disease
Number of subjects: 5900000

Group type: EXPERIMENTAL
Intervention: Antibiotics to reduce the reservoir of infection
Number of subjects: 5900000

Group type: COMPARATOR
Intervention: Health education and environmental improvement
Number of subjects: 5900000
Study: 10365647

Group type: EXPERIMENTAL
Intervention: Clozapine (plasma)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Norclozapine (plasma)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: MPO activity
Number of subjects: 57
Study: 8963479

Group type: EXPERIMENTAL
Intervention: 5 mg ramipril (ramiprilat)
Number of subjects: 0
Study: 1904206

Group type: EXPERIMENTAL
Intervention: Oximeter and capnograph
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Only oximeter
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Only capnograph
Number of subjects: 402

Group type: COMPARATOR
Intervention: Neither oximeter nor capnograph
Number of subjects: 402
Study: 6261369

Group type: EXPERIMENTAL
Intervention: Veralipride (100 mg/day for 20 days)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Beta-alanine (during the same period)
Number of subjects: 43
Study: 30179573

Group type: EXPERIMENTAL
Intervention: 20-week dialectical behavior therapy (DBT) skills training group
Number of subjects: 42
Study: 30497507

Group type: EXPERIMENTAL
Intervention: 2 g/day of phytosterols and 10 g/day of inulin-enriched soymilk
Number of subjects: 26

Group type: COMPARATOR
Intervention: Standard soymilk
Number of subjects: 26
Study: 29297641

Group type: EXPERIMENTAL
Intervention: Perimenopausal women
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Men in andropause
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (women)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (men)
Number of subjects: 111
Study: 24966398

Group type: EXPERIMENTAL
Intervention: Parent-directed intervention consisting of eight individual training sessions and a 3-month telephone support period.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Parent-directed intervention
Number of subjects: 44
Study: 22960644

Group type: EXPERIMENTAL
Intervention: Active monochromatic infrared energy (MIRE) therapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo MIRE therapy
Number of subjects: 73
Study: 20077171

Group type: EXPERIMENTAL
Intervention: 90 degrees rotation technique
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard technique (index finger insertion)
Number of subjects: 120
Study: 18821708

Group type: EXPERIMENTAL
Intervention: Glucosamine 500 mg 3 times daily
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 400 mg 3 times daily
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Combination of glucosamine and chondroitin sulfate
Number of subjects: 572

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg daily
Number of subjects: 572

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 572
Study: 15821826

Group type: EXPERIMENTAL
Intervention: Clonal thrombocytemia
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Reactive thrombocytosis
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 47
Study: 12388930

Group type: EXPERIMENTAL
Intervention: Colostrinin® (100 μg of PRP complex) taken every other day for three weeks, followed by a 2-week hiatus, for a total of 16 months (or 28 months for 13 patients).
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Colostrinin® (100 μg of PRP complex)
Number of subjects: 33
Study: 10063412

Group type: EXPERIMENTAL
Intervention: Four layer bandaging
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Healed ulceration
Number of subjects: 200

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 200
Study: 7554753

Group type: EXPERIMENTAL
Intervention: Constipated patients with delayed transit time
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Constipated patients (all)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 76
Study: 1971540

Group type: EXPERIMENTAL
Intervention: beta 1-blockade (atenolol, 50 mg, administered two times)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: beta 2-blockade (ICI 118,551, 50 mg, administered three times)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: beta 2-blockade
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: beta 1-blockade and beta 2-blockade
Number of subjects: 34
Study: 7026038

Group type: EXPERIMENTAL
Intervention: Heparin (1,000 units/ml) injected intraarterially at a dosage of 0.1 mg/kg prior to catheter removal
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo injected intraarterially at a dosage of 0.1 mg/kg prior to catheter removal
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Heparin (1,000 units/ml)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 30601417

Group type: EXPERIMENTAL
Intervention: Duloxetine (30 mg 1 day before surgery and for 6 weeks after surgery)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no duloxetine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 80
Study: 28284879

Group type: EXPERIMENTAL
Intervention: Eating Breakfast (EB)
Number of subjects: 20
Study: 25430996

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 3 mg testosterone enanthate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 6.25 mg testosterone enanthate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 12.5 mg testosterone enanthate
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: 25 mg testosterone enanthate
Number of subjects: 71
Study: 23594935

Group type: EXPERIMENTAL
Intervention: Needle aspiration with rapid on-site evaluation
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Needle aspiration without rapid on-site evaluation
Number of subjects: 125

Group type: COMPARATOR
Intervention: Conventional methods (forceps biopsy, brushing, bronchial washing)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Needle aspiration (with or without rapid on-site evaluation)
Number of subjects: 125
Study: 21464051

Group type: EXPERIMENTAL
Intervention: High-dose statin
Number of subjects: 3341

Group type: COMPARATOR
Intervention: Control (no statin/low-dose statin)
Number of subjects: 3341